Placental Stem Cell Therapy for Neurological Disorders Market Size is valued at USD 384.09 Mn in 2022 and is predicted to reach USD 2,049.44 Mn by the year 2031 at a 20.6% CAGR during the forecast period for 2023-2031.
Placental stem cell therapy for neurological disorders involves using stem cells derived from the placenta to treat various conditions affecting the nervous system. While this field of regenerative medicine shows promise, it is still an area of ongoing research, and clinical applications are not yet widely established. Increased awareness campaigns and educational efforts about the benefits and potential of placental stem cell therapies are raising awareness among healthcare professionals and patients, driving acceptance and adoption. Collaborations between research institutions, healthcare facilities, and biotech companies facilitate translating scientific discoveries into clinical applications, fostering market growth. Patients are increasingly seeking regenerative therapies that offer the potential for improved outcomes and a better quality of life, driving the demand for placental stem cell treatments.
Additionally, stringent regulatory requirements and approval processes can hinder the development and commercialization of placental stem cell therapies for neurological disorders. Meeting these regulatory standards can be time-consuming and costly. The availability of limited clinical data and long-term safety and efficacy data for placental stem cell therapies in treating neurological disorders may raise concerns among healthcare professionals and patients.
The placental stem cell therapy for neurological disorders market is segmented as Type and End-User. Based on type, the market is segmented as allogeneic placental stem cell therapy and autologous placental stem cell therapy. The end users segment consists of hospitals & speciality clinics, clinics, research organizations and research institutes & academics.
The autologous stem cell category will hold a major share in the global placental stem cell therapy for neurological disorders market 2022. Autologous stem cell therapy may provide the potential for long-term benefits, as the patient's cells are more likely to integrate and persist in the body without rejection. Autologous therapies eliminate the risk of disease transmission from donor-derived cells, which can be a concern with allogeneic therapies. This safety advantage is particularly crucial for patients with neurological disorders.
The hospitals & speciality clinics segment is growing rapidly in the global placental stem cell therapy for neurological Disorders market. Hospitals often have specialized medical teams with expertise in neurological disorders. Patients seek out hospitals for placental stem cell therapy due to the availability of skilled neurologists and neurosurgeons who can assess their conditions and recommend appropriate treatments. Hospitals typically have state-of-the-art diagnostic and treatment facilities, including advanced imaging technologies and operating rooms. These resources are essential for accurately diagnosing and effectively administering placental stem cell therapies for neurological disorders.
The North American placental stem cell therapy for neurological disorders market is expected to register the highest market share in revenue soon. Increasing awareness of placental stem cell therapies and their potential benefits has driven patient demand in North America. Patients with neurological disorders are actively seeking alternative treatments, contributing to market growth. Collaborations between academic institutions, healthcare providers, and biotechnology companies have led to establishing specialized centres for placental stem cell therapy in neurological disorders, fostering advancements and accessibility.
In addition, Asia Pacific is estimated to grow rapidly in the global placental stem cell therapy for neurological disorders market. The region benefits from a regulatory framework that facilitates the development and commercialization of regenerative therapies. Regulatory agencies, such as those in this region, have established clear pathways for approving stem cell therapies, providing a conducive environment for market growth.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 384.09 Mn |
|
Revenue Forecast In 2031 |
USD 2,049.44 Mn |
|
Growth Rate CAGR |
CAGR of 20.6 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Mesoblast Ltd., Pluristem Therapeutics, ReNeuron Group, AthersysInc., Cordlife India, LifeCell International Pvt. Ltd, Cryo-Cell International Inc., CBR Systems, Cellularity Inc., Cynata |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Placental Stem Cell Therapy for Neurological Disorders Market Snapshot
Chapter 4. Global Placental Stem Cell Therapy for Neurological Disorders Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type Estimates & Trend Analysis
5.1. By Type, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Type:
5.2.1. Allogeneic Placental Stem Cell Therapy
5.2.2. Autologous Placental Stem Cell Therapy
Chapter 6. Market Segmentation 2: By End-User Estimates & Trend Analysis
6.1. By End-User & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End-User:
6.2.1. Hospitals & Specialty Clinics
6.2.2. Clinics Research Organizations
6.2.3. Research Institutes & Academics
Chapter 7. Placental Stem Cell Therapy for Neurological Disorders Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) estimates and forecasts By Type, 2019-2031
7.1.2. North America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) estimates and forecasts By End-User, 2019-2031
7.1.3. North America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By Type, 2019-2031
7.2.2. Europe Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By End-User, 2019-2031
7.2.3. Europe Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By Type, 2019-2031
7.3.2. Asia Pacific Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By End-User, 2019-2031
7.3.3. Asia Pacific Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By Type, (US$ Million) 2019-2031
7.4.2. Latin America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
7.4.3. Latin America Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By Type, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders Market revenue (US$ Million) by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Mesoblast Ltd.,
8.2.2. Pluristem Therapeutics,
8.2.3. ReNeuron Group,
8.2.4. AthersysInc.,
8.2.5. Cordlife India,
8.2.6. LifeCell International Pvt. Ltd,
8.2.7. Cryo-Cell International Inc.,
8.2.8. CBR Systems,
8.2.9. Cellularity Inc., Cynata
Placental Stem Cell Therapy for Neurological Disorders Market By Type
Placental Stem Cell Therapy for Neurological Disorders Market By End-User
Placental Stem Cell Therapy for Neurological Disorders Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
